Hytrin and Pulmonary embolism - a phase IV clinical study of FDA data

Summary:

Pulmonary embolism is reported as a side effect among people who take Hytrin (terazosin hydrochloride), especially for people who are male, 60+ old, also take Plavix, and have Hypothyroidism.

The phase IV clinical study analyzes which people have Pulmonary embolism when taking Hytrin. It is created by eHealthMe based on reports of 7,298 people who have side effects when taking Hytrin from the FDA, and is updated regularly.

What is Hytrin?

Hytrin has active ingredients of terazosin hydrochloride. It is often used in prostate examination abnormal. eHealthMe is studying from 7,501 Hytrin users. Check the latest studies of Hytrin.

What is Pulmonary embolism?

Pulmonary embolism (blockage of the main artery of the lung) is found to be associated with 2,334 drugs and 2,958 conditions by eHealthMe. Check the latest studies of Pulmonary embolism.

On Jul, 31, 2026

7,298 people reported to have side effects when taking Hytrin.
Among them, 45 people (0.62%) have Pulmonary embolism.

Among these 45 people:

What is the gender of people who have Pulmonary embolism when taking Hytrin? *

female: 8.89 %
male: 91.11 %

What is the age of people who have Pulmonary embolism when taking Hytrin? *

What are other drugs people take besides Hytrin? *

What are other side effects people have besides Pulmonary embolism? *

Dyspnea (difficult or laboured breathing): 11 people, 24.44%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 10 people, 22.22%
Hypotension (abnormally low blood pressure): 10 people, 22.22%
Dizziness: 9 people, 20.00%
Pain: 8 people, 17.78%
Back Pain: 7 people, 15.56%
Diarrhea: 7 people, 15.56%
Chest Pain: 7 people, 15.56%
Weakness: 6 people, 13.33%
Oedema Peripheral (superficial swelling): 6 people, 13.33%

What are the existing conditions these people have? *

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 8.89%
Lung Cancer - Non-Small Cell (lung cancer): 3 people, 6.67%
Prostatomegaly (enlargement of the prostate): 3 people, 6.67%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 6.67%
High Blood Cholesterol: 3 people, 6.67%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 6.67%
Multiple Myeloma (cancer of the plasma cells): 3 people, 6.67%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 4.44%
Prostate Cancer Metastatic: 2 people, 4.44%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 4.44%

* Approximation only. Some reports may have incomplete information.

Do you take Hytrin and have Pulmonary embolism?

- Check whether Pulmonary embolism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Hytrin:

Hytrin (7,501 reports)

Browse all side effects of Hytrin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary embolism:

Pulmonary embolism (2,334 drugs)

Browse all the conditions that are associated with Pulmonary embolism:

Pulmonary embolism (2,958 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on terazosin hydrochloride (the active ingredients of Hytrin) and Hytrin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.